Terns Q2 net loss $22.7M; cash $225M; TERN-601 Ph1 data Sep, TERN-701 data Dec 2024

Terns Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.61

Net loss of $22.7M for Q2 2024 ($0.31/share) vs $17.9M ($0.25/share) in Q2 2023.
Cash, equivalents and marketable securities $225.3M, expected to fund operations into 2026.
Top-line Phase 1 data for oral GLP-1 TERN-601 (obesity) expected September 2024.
Interim Phase 1 CARDINAL trial data for allosteric BCR-ABL TERN-701 (CML) expected December 2024.
Appointed Elona Kogan as CLO; CFO search underway; Mark Vignola to serve through Jan 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.